| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | — | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | — | Trading Days | 108 |
| 52W High | 17.82 |
| 52W Low | 9.00 |
| % Off High | −29.63% |
| Ann. Volatility (1Y) | 99.93% | Ann. Volatility (3Y) | 99.93% |
| Sharpe (1Y) | 0.13 | Sharpe (3Y) | 0.13 |
| Max Drawdown (1Y) | −40.72% | Max Drawdown (3Y) | −40.72% |
| YTD | −14.40% | Since inception | −14.40% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| AMGN | AMGEN INC | $212.16B | 27.6 |
| GILD | GILEAD SCIENCES, INC. | $166.77B | 19.8 |
| RVMD | Revolution Medicines, Inc. | $39.09B | — |
| BIIB | BIOGEN INC. | $30.36B | 23.4 |
| MRNA | Moderna, Inc. | $22.14B | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $18.38B | 39.1 |
| EXEL | EXELIXIS, INC. | $14.20B | 20.3 |
| TECH | BIO-TECHNE Corp | $11.28B | 156.7 |
| KRYS | Krystal Biotech, Inc. | $10.74B | 53.3 |
| HALO | HALOZYME THERAPEUTICS, INC. | $9.90B | 32.6 |
| QGEN | QIAGEN N.V. | $9.17B | — |
| KYMR | Kymera Therapeutics, Inc. | $8.73B |
